International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 66

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–101) and Recommended (1–62) International Nonproprietary Names can be found in *Cumulative List No. 13, 2009* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 66

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–101) et recommandées (1–62) dans la *Liste récapitulative No. 13, 2009* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 66

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–101) y Recomendadas (1–62) se encuentran reunidas en *Cumulative List No. 13, 2009* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: *Recommended INN*	*Chemical name or description; Molecular formula; Graphic formula*
DCI Recommandée	*Nom chimique ou description; Formule brute; Formule développée*
DCI Recomendada	*Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada*

abediterolum

abediterol — 5-[(1*R*)-2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1*H*)-one

abéditérol — 5-[(1*R*)-2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl]-8-hydroxyquinoléin-2(1*H*)-one

abediterol — 5-[(1*R*)-2-{[6-(2,2-difluoro-2-feniletoxi)hexil]amino}-1-hidroxietil]-8-hidroxiquinolin-2(1*H*)-ona

$C_{25}H_{30}F_2N_2O_4$



adomiparinum natricum

adomiparin sodium — sodium salt of a low molecular mass heparin obtained by enzymatic depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy-α-L-*threo*-hex-4-enopyranuronic acid or it 4-hydroxy saturated derivative at the non-reducing end and a 2-amino-2-deoxy-D-glucopyranose derivative structure at the reducing end of their chain; the relative average molecular mass range is 5,500 to 9,000 daltons and a polydispersity of less than 1.5; the degree of sulfation is about 2.6 per disaccharidic unit

adomiparine sodique — sel sodique d'héparine de faible masse moléculaire obtenu par dépolymérisation enzymatique d'héparine de muqueuse intestinale de porc ; la majorité des composants possèdent une structure acide 4-déoxy-α-L-*thréo*-hex-4-énopyranuronique ou son dérivé saturé 4-hydroxylé à l'extrémité non réductrice de leur chaîne et une structure 2-amino-2-désoxy-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative est en moyenne comprise entre 5500 et 9000 et son indice de polymolécularité est inférieure à 1,5 ; le degré de sulfatation est d'environ 2,6 par unité disaccharide.

adomiparina sódica

sal sódica de heparina de baja masa molecular obtenida por despolimerización enzimática de heparina de mucosa intestinal de cerdo; la mayoría de cuyos componentes tienen un ácido 4-desoxi-α-L-*treo*-hex-4-enopiranurónico o su derivado saturado 4-hidroxilado en el extremo no reductor de la cadena y una 2-amino-2-desoxi-D-glucopiranosa en el reductor; la masa molecular relativa media está comprendida entre 5500 y 9000 y su índice de polidispersión es inférior a 1,5; el grado de sulfatación es aproximadamente 2,6 par unidad de disacárido.

aganepagum

aganepag

5-{3-[(2*S*)-1-{4-[(1*S*)-1-hydroxyhexyl]phenyl}-5-oxopyrrolidin-2-yl]propyl}thiophene-2-carboxylic acid

aganépag

acide 5-{3-[(2*S*)-1-{4-[(1*S*)-1-hydroxyhexyl]phényl}-5-oxopyrrolidin-2-yl]propyl}thiophène-2-carboxylique

aganepag

ácido 5-{3-[(2*S*)-1-{4-[(1*S*)-1-hidroxihexil]fenil}-5-oxopirrolidin-2-il]propil}tiofeno-2-carboxílico

$C_{24}H_{31}NO_4S$



alisertibum

alisertib

4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5*H*-pyrimido[5,4-*d*][2]benzazepin-2-yl]amino}-2-methoxybenzoic acid

alisertib

acide 4-{[9-chloro-7-(2-fluoro-6-méthoxyphényl)-5*H*-pyrimido[5,4-*d*][2]benzazépin-2-yl]amino}-2-méthoxybenzoïque

alisertib

ácido 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5*H*-pirimido[5,4-*d*][2]benzazepin-2-il]amino}-2-metoxibenzoico

$C_{27}H_{20}ClFN_4O_4$



alvelestatum

alvelestat

N-{[5-(methanesulfonyl)pyridin-2-yl]methyl}-6-methyl-5-(1-methyl-1*H*-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide

alvélestat

N-{[5-(méthanesulfonyl)pyridin-2-yl]méthyl}-6-méthyl-5-(1-méthyl-1*H*-pyrazol-5-yl)-2-oxo-1-[3-(trifluorométhyl)phényl]-1,2-dihydropyridine-3-carboxamide

alvelestat

N-{[5-(metanosulfonil)piridin-2-il]metil}-6-metil-5-(1-metil-1*H*-pirazol-5-il)-2-oxo-1-[3-(trifluorometil)fenil]-1,2-dihidropiridina-3-carboxamida

$C_{25}H_{22}F_3N_5O_4S$



amatuximabum #

amatuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MSLN (mesothelin, pre-pro-megakaryocyte-potentiating factor, megakaryocyte-potentiating factor, MPF, CAK1)], chimeric monoclonal antibody; gamma1 heavy chain (1-449) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (228-228'':231-231'')-bisdisulfide dimer

amatuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MSLN (mésothéline, facteur de potentialisation du pré-pro-mégacaryocyte, facteur de potentialisation des mégacaryocytes, MPF, CAK1)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-449) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (228-228'':231-231'')-bisdisulfure

amatuximab

inmunoglobulina G1-kappa, anti-[MSLN *de Homo sapiens* (mesotelina, factor de potenciación del pre-pro-megacariocito, factor de potenciación de megacariocitos, MPF, CAK1)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-449) [*Mus musculus* VH (IGHV1-37*01 -(IGHD)-IGHJ2*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-59*01 -IGKJ4*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGPE LEKPGASVKI SCKASGYSFT GYTMNWVKQS HGKSLEWIGL  50
ITPYNGASSY NQKFRGKATL TVDKSSSTAY MDLLSLTSED SAVYFCARGG 100
YDGRGFDYWG SGTPVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIELTQSPAI MSASPGEKVT MTCSASSSVS YMHWYQQKSG TSPKRWIYDT  50
SKLASGVPGR FSGSGSGNSY SLTISSVEAE DDATYYCQQW SKHPLTFGSG 100
TKVEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202   263-323   369-427
         22"-96"  146"-202" 263"-323" 369"-427"
Intra-L  23'-87'  133'-193'
         23'"-87'" 133'"-193'"
Inter-H-L 222-213' 222"-213'"
Inter-H-H 228-228" 231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

arbaclofenum

arbaclofen — (3*R*)-4-amino-3-(4-chlorophenyl)butanoic acid

arbaclofène — (-)-acide (3*R*)-4-amino-3-(4-chlorophényl)butanoïque

arbaclofeno — ácido (3*R*)-4-amino-3-(4-clorofenil)butanoico

$C_{10}H_{12}ClNO_2$



asfotasum alfa #

asfotase alfa — tissue-nonspecific alkaline phosphatase-IgG_1 fusion protein; human tissue-nonspecific isozyme alkaline phosphatase (AP-TNAP, EC=3.1.3.1) fusion protein with leucyl-lysyl-human immunoglobulin G1 Fc region {(6-15)-H-CH2-CH3 of IGHG1*03} fusion protein with aspartyl-isoleucyl-deca(aspartic acid), dimer (493-493':496-496')-bisdisulfide

asfotase alfa — protéine de fusion phosphatase alcaline humaine isozyme tissulaire non-spécifique-IgG1; phosphatase alcaline humaine isozyme tissulaire non-spécifique (AP-TNAP, EC=3.1.3.1) protéine de fusion avec la leucyl-lysyl-région Fc {(6-15)-H-CH2-CH3 de l'IGHG1*03} de l'immunoglobuline G1 humaine protéine de fusion avec l'aspartyl-isoleucyl-déca(acide aspartique), (493-493':496-496')-bisdisulfure du dimère

asfotasa alfa

proteína de fusión fosfatasa alcalina humana isozima tisular inespecífica-IgG1;
fosfatasa alcalina humana isozima tisular inespecífica (AP-TNAP, EC=3.1.3.1) proteína de fusión con la leucil-lisil-región Fc {(6-15)-H-CH2-CH3 del IGHG1*03} de la inmunoglobulinea G1 humana proteína de fusión con aspartil-isoleucil-deca(acide aspártico), (493-493':496-496')-bisdisulfuro del diméro

$C_{7108}H_{11008}N_{1968}O_{2206}S_{56}$ (peptide)

Monomer / Monomère / Monómero

```
LVPEKEKDPK  YWRDQAQETL  KYALELQKLN  TNVAKNVIMF  LGDGMGVSTV  50
TAARILKGQL  HHNPGEETRL  EMDKFPFVAL  SKTYNTNAQV  PDSAGTATAY  100
LCGVKANEGT  VGVSAATERS  RCNTTQGNEV  TSILRWAKDA  GKSVGIVTTT  150
RVNHATPSAA  YAHSADRDWY  SDNEMPPEAL  SQGCKDIAYQ  LMHNIRDIDV  200
IMGGGRKYMY  PKNKTDVEYE  SDEKARGTRL  DGLDLVDTWK  SFKPRYKHSH  250
FIWNRTELLT  LDPHNVDYLL  GLFEPGDMQY  ELNRNNVTDP  SLSEMVVVAI  300
QILRKNPKGF  FLLVEGGRID  HGHHEGKAKQ  ALHEAVEMDR  AIGQAGSLTS  350
SEDTLTVVTA  DHSHVFTFGG  YTPRGNSIFG  LAPMLSDTDK  KPFTAILYGN  400
GPGYKVVGGE  RENVSMVDYA  HNNYQAQSAV  PLRHETHGGE  DVAVFSKGPM  450
AHLLHGVHEQ  NYVPHVMAYA  ACIGANLGHC  APASSLKDKT  HTCPPCPAPE  500
LLGGPSVFLF  PPKPKDTLMI  SRTPEVTCVV  VDVSHEDPEV  KFNWYVDGVE  550
VHNAKTKPRE  EQYNSTYRVV  SVLTVLHQDW  LNGKEYKCKV  SNKALPAPIE  600
KTISKAKGQP  REPQVYTLPP  SREEMTKNQV  SLTCLVKGFY  PSDIAVEWES  650
NGQPENNYKT  TPPVLDSDGS  FFLYSKLTVD  KSRWQQGNVF  SCSVMHEALH  700
NHYTQKSLSL  SPGKDIDDDD  DDDDDD                              726
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
122-184 122'-184' 472-480 472'-480' 528-588
528'-588' 634-692 634'-692' 493-493' 496-496'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-123 Asn-123' Asn-213 Asn-213' Asn-254 Asn-254'
Asn-286 Asn-286' Asn-413 Asn-413' Asn-564 Asn-564'

atinumabum #

atinumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* RTN4 (reticulon 4, neurite outgrowth inhibitor, NOGO), isoform A], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-441) [*Homo sapiens* VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (220-220'':223-223'')-bisdisulfide dimer

atinumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* RTN4 (réticulon 4, inhibiteur de la croissance des neurites, NOGO), isoforme A], *Homo sapiens* anticorps monoclonal;chaîne lourde gamma4 (1-441) [*Homo sapiens* VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (220-220'':223-223'')-bisdisulfure

atinumab

inmunoglobulina G4-kappa, anti-[RTN4 de *Homo sapiens* (reticulón 4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-441) [VH *de Homo sapiens* (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (220-220'':223-223'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMSWVRQA PGKGLEWVAT  50
IKQDGSQKNY VDSVKGRFTI SRDNAKNSLY LRLNSLRAED TAVYYCATEL 100
FDLWGRGSLV TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 150
VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD 200
HKPSNTKVDK RVESKYGPPC PSCPAPEFLG GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRVVSVL 300
TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400
YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K          441
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 141-197 255-315 361-419
22"-96" 141"-197" 255"-315" 361"-419"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 128-214' 128"-214'"
Inter-H-H 220-220" 223-223"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
291, 291"

atopaxarum

atopaxar — 2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2*H*-isoindol-2-yl)-1-[3-*tert*-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethan-1-one

atopaxar — 2-(5,6-diéthoxy-7-fluoro-1-imino-1,3-dihydro-2*H*-isoindol-2-yl)-1-[3-*tert*-butyl-4-méthoxy-5-(morpholin-4-yl)phényl]éthanone

atopaxar — 2-(5,6-dietoxi-7-fluoro-1-imino-1,3-dihidro-2*H*-isoindol-2-il)-1-[3-*terc*-butil-4-metoxi-5-(morfolin-4-il)fenil]etan-1-ona

$C_{29}H_{38}FN_3O_5$



bisegliptinum

bisegliptin — ethyl 4-({2-[(2*S*,4*S*)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoethyl}amino)bicyclo[2.2.2]octane-1-carboxylate

biségliptine — 4-({2-[(2*S*,4*S*)-2-cyano-4-fluoropyrrolidin-1-yl]-2-oxoéthyl}amino)bicyclo[2.2.2]octane-1-carboxylate d'éthyle

bisegliptina — 4-({2-[(2*S*,4*S*)-2-ciano-4-fluoropirrolidin-1-il]-2-oxoetil}amino)biciclo[2.2.2]octano-1-carboxilato de etilo

$C_{18}H_{26}FN_3O_3$



burixaforum

burixafor — (2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(cyclohexylamino)propyl]amino}methyl)cyclohexyl]methyl}amino) pyrimidin-4-yl]piperazin-1-yl}ethyl)phosphonic acid

burixafor — acide (2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(cyclohexylamino)propyl]amino}méthyl)cyclohexyl]méthyl}amino) pyrimidin-4-yl]pipérazin-1-yl}éthyl)phosphonique

burixafor — ácido (2-{4-[6-amino-2-({[(1*r*,4*r*)-4-({[3-(ciclohexilamino)propil]amino}metil)ciclohexil]metil}amino)pirimidin-4-il]piperazin-1-il}etil)fosfónico

$C_{27}H_{51}N_8O_3P$



cadazolidum

cadazolid — 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid

cadazolid — acide 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hydroxyméthyl)-2-oxo-1,3-oxazolidin-3-yl]phénoxy}méthyl)-4-hydroxypipéridin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

cadazolid — ácido 1-ciclopropil-6-fluoro-7-[4-({2-fluoro-4-[(5*R*)-5-(hidroximetil)-2-oxo-1,3-oxazolidin-3-il]fenoxi}metil)-4-hidroxipiperidin-1-il]-4-oxo-1,4-dihidroquinolin-3-carboxílico

$C_{29}H_{29}F_2N_3O_8$



carlumabum #

carlumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CCL2 (chemokine (C-C motif) ligand 2, C-C motif chemokine 2, monocyte chemoattractant protein-1, MCP-1, monocyte chemotactic and activating factor, MCAF, small inducible cytokine A2, SCYA2, HC11)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; (228-228":231-231")-bisdisulfide dimer

carlumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CCL2 (chimiokine (C-C motif) ligand 2, C-C motif chimiokine 2, protéine 1 chimioattractante du monocyte, MCP-1, facteur activateur et chimiotactique du monocyte, MCAF, SCYA2, HC11)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfure avec la chaîne légère kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimère (228-228":231-231")-bisdisulfure

carlumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CCL2 (quimiokina (C-C motif) ligando 2, C-C motif quimiokina 2, proteìna 1 quimiotàctica de monocito, MCP-1, factor activador y quimiotàctico de monocito, MCAF, SCYA2, HC11)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV1-69*01 (99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)), (222-216')-disulfuro con la cadena ligera kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dìmero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYGISWVRQA PGQGLEWMGG  50
IIPIFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD 100
GIYGELDFWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS DAYLAWYQQK PGQAPRLLIY  50
DASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCH QYIQLHSFTF 100
GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150
KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200
QGLSSPVTKS FNRGEC                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96    146-202    263-323    369-427
          22"-96"  146"-202"  263"-323"  369"-427"
Intra-L   23'-89'    136'-196'
          23'"-89'"  136'"-196'"
Inter-H-L 222-216'  222"-216'"
Inter-H-H 228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

cenisertibum

cenisertib

(1*S*,2*S*,3*R*,4*R*)-3-{[5-fluoro-2-({3-methyl-4-(4-methylpiperazin-1-yl)phenyl}amino)pyrimidin-4-yl]amino}bicyclo[2.2.1]hept-5-ene-2-carboxamide

cénisertib

(1*S*,2*S*,3*R*,4*R*)-3-[(5-fluoro-2-{[3-méthyl-4-(4-méthylpipérazin-1-yl)phényl]amino}pyrimidin-4-yl)amino]bicyclo[2.2.1]hept-5-ène-2-carboxamide

cenisertib

(1*S*,2*S*,3*R*,4*R*)-3-{[5-fluoro-2-({3-metil-4-(4-metilpiperazin-1-il)fenil}amino)pirimidin-4-il]amino}biciclo[2.2.1]hept-5-eno-2-carboxamida

$C_{24}H_{30}FN_7O$



crolibulinum

crolibulin	(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-dimethoxyphenyl)-4*H*-chromene-3-carbonitrile
crolibuline	(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-diméthoxyphényl)-4*H*-chromène-3-carbonitrile
crolibulina	(4*R*)-2,7,8-triamino-4-(3-bromo-4,5-dimetoxifenil)-4*H*-cromeno-3-carbonitrilo

$C_{18}H_{17}BrN_4O_3$



darexabanum

darexaban	*N*-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
darexaban	*N*-[2-hydroxy-6-(4-méthoxybenzamido)phényl]-4-(4-méthyl-1,4-diazépan-1-yl)benzamide
darexabán	*N*-[2-hidroxi-6-(4-metoxibenzamido)fenil]-4-(4-metil-1,4-diazepan-1-il)benzamida

$C_{27}H_{30}N_4O_4$



delamanidum

delamanid (2*R*)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-*b*][1,3]oxazole

délamanid (2*R*)-2-méthyl-6-nitro-2-[(4-{4-[4-(trifluorométhoxy)phénoxy]pipéridin-1-yl}phénoxy)méthyl]-2,3-dihydroimidazo[2,1-*b*]oxazole

delamanid (2*R*)-2-metil-6-nitro-2-[(4-{4-[4-(trifluorometoxi)fenoxi]piperidin-1-il}fenoxi)metil]-2,3-dihidroimidazo[2,1-*b*][1,3]oxazol

$C_{25}H_{25}F_3N_4O_6$



edivoxetinum

edivoxetine (1*R*)-2-(5-fluoro-2-methoxyphenyl)-1-[(2*S*)-morpholin-2-yl]-1-(oxan-4-yl)ethan-1-ol

édivoxétine (1*R*)-2-(5-fluoro-2-méthoxyphényl)-1-[(2*S*)-morpholin-2-yl]-1-(oxan-4-yl)éthan-1-ol

edivoxetina (1*R*)-2-(5-fluoro-2-metoxifenil)-1-[(2*S*)-morfolin-2-il]-1-(oxan-4-il)etan-1-ol

$C_{18}H_{26}FNO_4$



efinaconazolum

efinaconazole (2*R*,3*R*)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1*H*-1,2,4-triazin-1-yl)butan-2-ol

éfinaconazole (2*R*,3*R*)-2-(2,4-difluorophényl)-3-(4-méthylènepipéridin-1-yl)-1-(1*H*-1,2,4-triazol-1-yl)butan-2-ol

efinaconazol (2*R*,3*R*)-2-(2,4-difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1*H*-1,2,4-triazin-1-il)butan-2-ol

$C_{18}H_{22}F_2N_4O$



egaptivonum pegolum

egaptivon pegol

a pegylated aptamer which binds von Willebrand factor; 5'-*O*-{[6-(carboxyamino)hexyl]hydroxyphosphoryl}-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-*O*-methyl-*P*-thioguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→5')-2'-*O*-methylguanylyl-(3'→5')-2'-*O*-methylcytidylyl-(3'→3')-thymidine, carbamate ester with monomethyl ether of polyethylene gycol (20 kDa)

egaptivon pégol

aptamère pégylé qui se lie au facteur de von Willebrand; ester carbamique entre l'éther monométhylique du polyéthylèneglycol (macrogol 20 kDa) et le 5'-*O*-{[6-(carboxyamino)hexyl]hydroxyphosphoryl}-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-désoxyadénylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-*O*-méthyl-*P*-thioguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-2'-désoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-désoxycytidylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→5')-2'-*O*-méthylguanylyl-(3'→5')-2'-*O*-méthylcytidylyl-(3'→3')-thymidine

egaptivón pegol

aptámero pegilado que se une al factor de von Willebrand; éster carbámico entre el éter monometílico del polietilenglicol (macrogol 20 kDa) y el 5'-*O*-{[6-(carboxiamino)hexil]hidroxifosforil}-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-*O*-metil-*P*-tioguanilil-(3'→5')-timidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metiluridilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-*O*-mtiladenilil-(3'→5')-2'-*O*-metilcitidilil-(3'→5')-2'-*O*-metilguanilil-(3'→5')-2'-*O*-metilcitidilil-(3'→3')-timidina

$C_{413}H_{546}N_{144}O_{275}P_{40}S\ (C_2H_4O)_n$



(3'-5')(p−Gm−Cm−Gm−Um−dG−dC−dA−Gm−Um−Gm−Cm−Cm−
Um−Cm−Gm−Gm−Cm−dC−Gm−sp−dT−Gm−dC−dG−dG−dT−Gm−
Gm−Cm−dC−Um−dC−dC−Gm−Um−dC−Am−Cm−Gm−Cm3'−3'dT)

elobixibatum

elobixibat

[(2*R*)-2-(2-{[3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1*H*-1λ^6,5-benzothiazepin-8-yl]oxy}acetamido)-2-phenylacetamido]acetic acid

élobixibat

acide [(2*R*)-2-(2-{[3,3-dibutyl-7-(méthylsulfanyl)-1,1-dioxo-5-phényl-2,3,4,5-tétrahydro-1*H*-1λ^6,5-benzothiazépin-8-yl]oxy}acétamido)-2-phénylacétamido]acétique

elobixibat

ácido [(2*R*)-2-(2-{[3,3-dibutil-5-fenil-7-(metilsulfanil)-1,1-dioxo-2,3,4,5-tetrahidro-1*H*-1λ^6,5-benzotiazepin-8-il]oxi}acetamido)-2-fenilacetamido]acético

$C_{36}H_{45}N_3O_7S_2$



elsiglutidum

elsiglutide — [2-glycine(A>G),3-glutamic acid(D>E),8-serine(D>S),10-leucine(M>L),11-serine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]human glucagon-like peptide 2 (GLP-2) fusion protein with hexalysinamide

elsiglutide — [2-glycine(A>G),3-acide glutamique(D>E),8-sérine(D>S),10-leucine(M>L),11-sérine(N>S),16-alanine(N>A),24-alanine(N>A),28-alanine(Q>A)]peptide 2 semblable au glucagon humain (GLP-2) protéine de fusion avec l'hexalysinamide

elsiglutida — [2-glicina(A>G),3-acide glutámico(D>E), 8-serina(D>S),10-leucina(M>L),11-serina(N>S),16-alanina(N>A),24-alanina(N>A),28-alanina(Q>A)]péptido 2 similar al glucagón humano(GLP-2) proteína de fusión con hexalisinamida

$C_{196}H_{323}N_{53}O_{56}$

HGEGSFSSEL STILDALAAR DFIAWLIATK ITDKKKKK<u>K</u> 39

Modified residue / Résidu modifié / Residuo modificado
<u>K</u> lysinamide

empagliflozinum

empagliflozin — (1*S*)-1,5-anhydro-1-*C*-{4-chloro-3-[(4-{[(3*S*)-oxolan-3-yl]oxy}phenyl)methyl]phenyl}-D-glucitol

empagliflozine — (1*S*)-1,5-anhydro-1-*C*-{4-chloro-3-[(4-{[(3*S*)-oxolan-3-yl]oxy]}phényl)méthyl]phényl}-D-glucitol

empagliflozina — (1*S*)-1,5-anhidro-1-*C*-{4-cloro-3-[(4-{[(3*S*)-oxolan-3-il]oxi}fenil)metil]fenil}-D-glucitol

$C_{23}H_{27}ClO_7$



enavatuzumabum #

enavatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF12A (tumor necrosis factor receptor superfamily member 12A, fibroblast growth factor (FGF)-inducible 14 kDa protein, Fn14, TNF-like weak inducer of apoptosis (Tweak) receptor, Tweak receptor, TweakR, CD266], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (84.80%) - IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (228-228":231-231")-bisdisulfide dimer

énavatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TNFRSF12A (membre 12A de la superfamille des récepteurs du facteur de nécrose tumorale, protéine de 14 kDa induite par le facteur de croissance du fibroblaste (FGF), Fn14, TNF-like faible inducteur d'apoptose (Tweak), récepteur de Tweak, CD266], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (84.80%) - IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (228-228":231-231")-bisdisulfure

enavatuzumab

inmunoglobulina G1-kappa, anti-[TNFRSF12A de *Homo sapiens* (miembro 12A de la superfamilia de receptores del factor de necrosis tumoral, proteína de 14 kDa inducida por el factor de crecimiento de fibroblastos (FGF), Fn14, TNF-like débil inductor de apoptosis (Tweak), receptor de Tweak, CD266], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV3-7*01 (86.70%) -(IGHD)-IGHJ6*01 T123>L (114)) [8.10.10] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360) (120-449)], (222-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (84.80%) - IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMSWVRQA PGKGLEWVAE  50
IRLKSDNYAT HYAESVKGRF TISRDDSKNS LYLQMNSLRA EDTAVYYCTG 100
YYADAMDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQSVS TSSYSYMHWY QQKPGKAPKL  50
LIKYASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQHSWEIPY 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-98    146-202    263-323    369-427
         22"-98"  146"-202"  263"-323"  369"-427"
Intra-L  23'-92'   138'-198'
         23'"-92'" 138'"-198'"
Inter-H-L  222-218'  222"-218'"
Inter-H-H  228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299"

enokizumabum #

enokizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL9 (interleukin 9, IL-9, T cell growth factor p40)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (231-231":234-234")-bisdisulfide dimer

énokizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* IL9 (interleukine 9, IL-9, facteur de croissance p40 des cellules T)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

enokizumab — inmunoglobulina G1-kappa, anti-[IL9 de *Homo sapiens* (interleukina 9, IL-9, factor de crecimiento p40 de células T)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-452) [VH humanizada (*Homo sapiens* IGHV1-69*11 (87.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (83.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGGTFS YYWIEWVRQA PGQGLEWMGE  50
ILPGSGTTNP NEKFKGRVTI TADESTSTAY MELSSLRSED TAVYYCARAD 100
YYGSDYVKFD YWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQHVI THVTWYQQKP GKAPKLLIYG  50
TSYSYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FYEYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 149-205 266-326 372-430
22"-96" 149"-205" 266"-326" 372"-430"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 225-214' 225"-214'"
Inter-H-H 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
302, 302"

erteberelum

erteberel — (3a*S*,4*R*,9b*R*)-4-(4-hydroxyphenyl)-1,2,3,3a,4,9b-hexahydrocyclopenta[*c*]chromen-8-ol

ertébérel — (3a*S*,4*R*,9b*R*)-4(4-hydroxyphényl)-1,2,3,3a,4,9b-hexahydrocyclopenta[*c*][1]chromén-8-ol

erteberel

(3a*S*,4*R*,9b*R*)-4-(4-hidroxifenil)-1,2,3,3a,4,9b-hexahidrociclopenta[*c*]cromen-8-ol

$C_{18}H_{18}O_3$



etrolizumabum #

etrolizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* integrins ITGA4_ITGB7 (integrin alpha4 (CD49d)_beta7, integrin α4β7, lymphocyte Peyer's patch adhesion molecule 1, LPAM-1) and ITGAE_ITGB7 (integrin alphaE (CD103, alphaIEL)_beta7, integrin αEβ7, HML-1], humanized monoclonal antibody;
gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens* IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (226-226":229-229")-bisdisulfide dimer

étrolizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* intégrines ITGA4_ITGB7 (intégrine alpha4 (CD49d)_bêta7, intégrine α4β7, récepteur d'adressage spécifique des plaques de Peyer, LPAM-1) et ITGAE_ITGB7 (intégrine alphaE (CD103, alphaIEL)_bêta7, intégrine αEβ7, HML1)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens* IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (226-226":229-229")-bisdisulfure

etrolizumab

immunoglobuline G1-kappa, anti-[integrinas ITGA4_ITGB7 de *Homo sapiens* (integrina alfa4 (CD49d)_beta7, integrina α4β7, molécula de adhesión específica de linfocitos de las placas de Peyer, LPAM-1) e ITGAE_ITGB7 (integrina alfaE (CD103, alfaIEL)_beta7, integrina αEβ7, HML1)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-446) [VH humanizada (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ4*01) [8.7.11] (1-117) -*Homo sapiens* IGHG1*01 CH3 D12>E (356), L14>M (358), K130>del (118-446)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ1*01) [6.4.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFFIT NNYWGWVRQA PGKGLEWVGY  50
ISYSGSTSYN PSLKSRFTIS RDTSKNTFYL QMNSLRAEDT AVYYCARTGS 100
SGYFDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASESVD DLLHWYQQKP GKAPKLLIKY  50
ASQSISGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ GNSLPNTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	144-200	261-321	367-425
	22"-95"	144"-200"	261"-321"	367"-425"
Intra-L	23'-88'	134'-194'		
	23'"-88'"	134'"-194'"		
Inter-H-L	220-214'	220"-214'"		
Inter-H-H	226-226"	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
297, 297"

florbenazinum (^{18}F)

florbenazine (^{18}F) (2*R*,3*R*,11b*R*)-9-(3-[^{18}F]fluoropropoxy)-10-methoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2*H*-pyrido[2,1-*a*]isoquinolin-2-ol

florbénazine (^{18}F) (2*R*,3*R*,11b*R*)-9-(3-[^{18}F]fluoropropoxy)-10-méthoxy-3-(2-méthylpropyl)-1,3,4,6,7,11b-hexahydro-2*H*-pyrido[2,1-*a*]isoquinoléin-2-ol

florbenazina (^{18}F) (2*R*,3*R*,11b*R*)-9-(3-[^{18}F]fluoropropoxi)-3-(2-metilpropil)-10-metoxi-1,3,4,6,7,11b-hexahidro-2*H*-pirido[2,1-*a*]isoquinolin-2-ol

$C_{21}H_{32}{}^{18}FNO_3$



forigerimodum

forigerimod *O*^{3,140}-phosphono(human U1 small nuclear ribonucleoprotein 70 kDa (snRNP70))-(131-151)-peptide

forigérimod *O*^{3,140}-phosphono(petite ribonucléoprotéine nucléaire U1 humaine de 70 kDa (snRNP70))-(131-151)-peptide

forigerimod *O*^{3,140}-fosfono(pequeña ribonucleoproteína nuclear U1 humana de 70 kDa (snRNP70))-(131-151)-péptido

$C_{117}H_{181}N_{34}O_{32}PS$

RIHMVYSKRS GKPRGYAFIE Y 21

Modified residues / Résidus modifiés / Residuos modificados

S
10
O3,10-phosphono
(phosphoserine)



fulranumabum #

fulranumab — immunoglobulin G2-kappa, anti-[*Homo sapiens* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225'':226-226':229-229'':232-232''')-tetrakisdisulfide dimer

fulranumab — immunoglobuline G2-kappa, anti-[*Homo sapiens* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma2 (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':226-226':229-229'':232-232''')-tétrakisdisulfure

fulranumab — inmunoglobulina G2-kappa, anti-[NGF de *Homo sapiens* (factor de crecimiento de nervios, factor de crecimiento de nervios polipétido beta, NGFB, beta-NGF)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma2 (1-449) [*Homo sapiens* VH (IGHV3-48*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -IGHG2*01 (124-449)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (100.00%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':226-226':229-229'':232-232''')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTLR SYSMNWVRQA PGKGLEWVSY  50
ISRSSHTIFY ADSVKGRFTI SRDNAKNSLY LQMDSLRDED TAMYYCARVY 100
SSGWHVSDYF DYWGQGILVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSNFG 200
TQTYTCNVDH KPSNTKVDKT VERKCCVECP PCPAPPVAGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
TFRVVSVLTV VHQDWLNGKE YKCKVSNKGL PAPIEKTISK TKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPML 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALAWYQQKP GKAPKLLIYD  50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 150-206 263-323 369-427
22''-96'' 150''-206'' 263''-323'' 369''-427''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 137-214' 137''-214'''
Inter-H-H 225-225'' 226-226'' 229-229'' 232-232''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299''

gaxilosum

gaxilose	4-*O*-β-D-galactopyranosyl-D-xylose
gaxilose	4-*O*-β-D-galactopyranosyl-D-xylose
gaxilosa	4-*O*-β-D-galactopiranosil-D-xilosa

$C_{11}H_{20}O_{10}$



gevokizumabum #

gevokizumab	immunoglobulin G2-kappa, anti-[*Homo sapiens* IL1B (interleukin 1 beta, 1L1F2, IL-1B)], humanized monoclonal antibody; gamma2 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens* IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (222-222":223-223":226-226":229-229")-tetrakisdisulfide dimer
gévokizumab	immunoglobuline G2-kappa, anti-[*Homo sapiens* IL1B (interleukine 1 bêta, 1L1F2, IL-1B)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-445) [VH humanisé (*Homo sapiens* IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens* IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (222-222":223-223":226-226":229-229")-tétrakisdisulfure
gevokizumab	inmunoglobulina G2-kappa, anti-[IL1B *de Homo sapiens* (interleukina 1 beta, 1L1F2, IL-1B)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-445) [VH humanizada (*Homo sapiens* IGHV2-5*10 (72.70%) -(IGHD)-IGHJ5*01) [10.7.12] (1-120) -*Homo sapiens* IGHG2*02 CH3 K130>del (121-445)], (134-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (82.10%) -IGKJ1*01 V124>L (104')) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (222-222":223-223":226-226":229-229")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCSFSGFSLS TSGMGVGWIR QPSGKGLEWL  50
AHIWWDGDES YNPSLKSRLT ISKDTSKNQV SLKITSVTAA DTAVYFCARN 100
RYDPPWFVDW GQGTLVTVSS ASTKGPSVFP LAPCSRSTSE STAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VTSSNFGTQT 200
YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVQFNWYVDG MEVHNAKTKP REEQFNSTFR 300
VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPMLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSTSS LSASVGDRVT ITCRASQDIS NYLSWYQQKP GKAVKLLIYY  50
TSKLHSGVPS RFSGSGSGTD YTLTISSLQQ EDFATYFCLQ GKMLPWTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-97 147-203 260-320 366-424
22"-97" 147"-203" 260"-320" 366"-424"
Intra-L 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L 134-214' 134"-214'"
Inter-H-H 222-222" 223-223" 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
296, 296"

granotapidum
granotapide — diethyl 2-({2-[3-(dimethylcarbamoyl)-4-{4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido}phenyl]acetyloxy}methyl)-2-phenylpropanedioate

granotapide — 2-[({2-[3-(diméthylcarbamoyl)-4-({[4'-(trifluorométhyl)-[1,1'-biphényl]-2-yl-carboxamido)phényl]acétyl}oxy)méthyl]-2-phénylpropanedioate de diéthyle

granotapida — 2-({2-[3-(dimetilcarbamoil)-4-{4'-(trifluorometil)-[1,1'-bifenil]-2-carboxamido}fenil]acetiloxi}metil)-2-fenilpropanodioato de dietilo

$C_{39}H_{37}F_3N_2O_8$



icrucumabum #
icrucumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)], (229-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9] (1'-108') -IGKC1*01 (109'-215')]; (235-235":238-238")-bisdisulfide dimer

icrucumab	immunoglobuline G1 kappa, anti-[*Homo sapiens* FLT1 (tyrosine kinase 1 apparentée au fms, récepteur 1 du facteur de croissance endothélial vasculaire, VEGFR-1, VEGFR, FLT, FRT, récepteur du facteur de perméabilité vasculaire)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)), (229-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9] (1'-108') -IGKC1*01 (109'-215')]; dimère (235-235":238-238")-bisdisulfure
icrucumab	inmunoglobulina G1 kappa, anti-[*Homo sapiens* FLT1 (tirosin kinasa 1 emparentada con el fms, receptor 1 del factor de crecimiento endotelial vascular, VEGFR-1, VEGFR, FLT, FRT, receptor del factor de permeabilidad vascular)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-456) [*Homo sapiens* VH (IGHV3-33*01 (93.90%) -(IGHD)-IGHJ6*01 [8.8.19] (1-126) -IGHG1*03 (127-456)), (229-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ4*01) [7.3.9] (1'-108') -IGKC1*01 (109'-215')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QAQVVESGGG VVQSGRSLRL SCAASGFAFS SYGMHWVRQA PGKGLEWVAV  50
IWYDGSNKYY ADSVRGRFTI SRDNSENTLY LQMNSLRAED TAVYYCARDH 100
YGSGVHHYFY YGLDVWGQGT TVTVSSASTK GPSVFPLAPS SKSTSGGTAA 150
LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKRVEPKSCD KTHTCPPCPA PELLGGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG 350
QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK                                                 456
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASQSVS SSYLAWYQQK PGQAPRLLIY  50
GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSPLTFG 100
GGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH KVYACEVTHQ 200
GLSSPVTKSF NRGEC                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    153-209    270-330    376-434
         22"-96"  153"-209"  270"-330"  376"-434"
Intra-L  23'-89'   135'-195'
         23'"-89'" 135'"-195'"
Inter-H-L  229-215'  229"-215'"
Inter-H-H  235-235"  238-238"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

306, 306"

irosustatum

irosustat	6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[*c*]chromen-3-yl sulfamate
irosustat	sulfamate de 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[*c*]chromèn-3-yle
irosustat	sulfamato de 6-oxo-6,7,8,9,10,11-hexahidrociclohepta[*c*]cromen-3-ilo

$C_{14}H_{15}NO_5S$



ivacaftorum

ivacaftor	*N*-(2,4-di-*tert*-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide
ivacaftor	*N*-[2,4-di-*tert*-butyl-5-hydroxyphényl]-4-oxo-1,4-dihydroquinoléine-3-carboxamide
ivacaftor	*N*-(2,4-di-*terc*-butil-5-hidroxifenil)-4-oxo-1,4-dihidroquinolina-3-carboxamida

$C_{24}H_{28}N_2O_3$



ixazomibum

ixazomib	{(1*R*)-1-[(2,5-dichlorobenzamido)acetamido]-3-methylbutyl}boronic acid
ixazomib	acide [(1*R*)-1-{[*N*-(2,5-dichlorobenzoyl)glycyl]amino}-3-méthylbutyl]boronique
ixazomib	acido {(1*R*)-1-[(2,5-diclorobenzamido)acetamido]-3-metilbutil]borónico

$C_{14}H_{19}BCl_2N_2O_4$



lenvatinibum

lenvatinib	4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
lenvatinib	4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phénoxy}-7-méthoxyquinoléine-6-carboxamide
lenvatinib	4-{3-cloro-4-[(ciclopropilcarbamoil)amino]fenoxi}-7-metoxiquinolina-6-carboxamida

$C_{21}H_{19}ClN_4O_4$



letaxabanum

letaxaban — 1-(1-{(2*S*)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}piperidin-4-yl)tetrahydropyrimidin-2(1*H*)-one

létaxaban — 1-(1-{(2*S*)-3-[(6-chloronaphtalén-2-yl)sulfonyl]-2-hydroxypropanoyl}pipéridin-4-yl)tétrahydropyrimidin-2(1*H*)-one

letaxabán — 1-(1-{(2*S*)-3-[(6-cloronaftalen-2-il)sulfonil]-2-hidroxipropanoil}piperidin-4-il)tetrahidropirimidin-2(1*H*)-ona

$C_{22}H_{26}ClN_3O_5S$



letermovirum

letermovir — (4*S*)-2-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid

létermovir — acide {(4*S*)-8-fluoro-2-[4-(3-méthoxyphényl)pipérazin-1-yl]-3-[2-méthoxy-5-(trifluorométhyl)phényl]-3,4-dihydroquinazolin-4-yl}acétique

letermovir — ácido (4*S*)-2-{8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-3,4-dihidroquinazolin-4-il}acético

$C_{29}H_{28}F_4N_4O_4$



levoglucosum

levoglucose	L-glucose
lévoglucose	L-glucose
levoglucosa	L-glucosa

$C_6H_{12}O_6$



linsitinibum

linsitinib	(1*s*,3*r*)-3-[8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-*a*]pyrazin-3-yl]-1-methylcyclobutan-1-ol
linsitinib	(1*s*,3*r*)-3-[8-amino-1-(2-phénylquinoléin-7-yl)imidazo[1,5-*a*]pyrazin-3-yl]-1-méthylcyclobutan-1-ol
linsitinib	(1*s*,3*r*)-3-[8-amino-1-(2-fenilquinolin-7-il)imidazo[1,5-*a*]pirazin-3-il]-1-metilciclobutan-1-ol

$C_{26}H_{23}N_5O$



luseogliflozinum

luseogliflozin	(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-ethoxyphenyl)methyl]-2-methoxy-4-methylphenyl}-6-(hydroxymethyl)thiane-3,4,5-triol
luséogliflozine	(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-éthoxyphényl)méthyl]-2-méthoxy-4-méthylphényl}-6-(hydroxyméthyl)thiane-3,4,5-triol
luseogliflozina	(2*S*,3*R*,4*R*,5*S*,6*R*)-2-{5-[(4-etoxifenil)metil]-4-metilfenil-2-metoxi}-6-(hidroximetil)tiano-3,4,5-triol

$C_{23}H_{30}O_6S$



lusutrombopagum

lusutrombopag — (2*E*)-3-{2,6-dichloro-4-[(4-{3-[(1*S*)-1-(hexyloxy)ethyl]-2-methoxyphenyl}-1,3-thiazol-2-yl)carbamoyl]phenyl}-2-methylprop-2-enoic acid

lusutrombopag — acide (2*E*)-3-{2,6-dichloro-4-[(4-{3-[(1*S*)-1-(hexyloxy)éthyl]-2-méthoxyphényl}-1,3-thiazol-2-yl)carbamoyl]phényl}-2-méthylprop-2-énoïque

lusutrombopag — ácido (2*E*)-3-{2,6-dicloro-4-[(4-{3-[(1*S*)-1-(hexiloxi)etil]-2-metoxifenil}-1,3-tiazol-2-il)carbamoil]fenil}-2-metilprop-2-enoico

$C_{29}H_{32}Cl_2N_2O_5S$



mavoglurantum

mavoglurant — methyl (3a*R*,4*S*,7a*R*)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]octahydro-1*H*-indole-1-carboxylate

mavoglurant — (3a*R*,4*S*,7a*R*)-4-hydroxy-4-[2-(3-méthylphényl)éthynyl]octahydro-1*H*-indole-1-carboxylate de méthyle

mavoglurant — (3a*R*,4*S*,7a*R*)-4-hidroxi-4-[2-(3-metilfenil)etinil]octahidro-1*H*-indol-1-carboxilato de metil

$C_{19}H_{23}NO_3$



mogamulizumabum #

mogamulizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* CCR4 (chemokine (C-C motif) receptor 4, CC chemokine receptor 4, CCR-4, CKR4, k5-5, CD194)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer

mogamulizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* CCR4 (récepteur 4 de chimiokine (C-C motif), récepteur 4 de chimiokine CC, CCR-4, CKR4, k5-5, CD194)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure

mogamulizumab

inmunoglobulina G1-kappa, anti-[CCR4 de *Homo sapiens* (receptor 4 de quimiokina (C-C motif), receptor 4 de quimiokina CC, CCR-4, CKR4, k5-5, CD194)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV3-21*01 (83.70%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-29*02 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
```
EVQLVESGGD LVQPGRSLRL SCAASGFIFS NYGMSWVRQA PGKGLEWVAT  50
ISSASTYSYY PDSVKGRFTI SRDNAKNSLY LQMNSLRVED TALYYCGRHS 100
DGNFAFGYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera
```
DVLMTQSPLS LPVTPGEPAS ISCRSSRNIV HINGDTYLEW YLQKPGQSPQ  50
LLIYKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSLLP 100
WTFGQGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
```
Intra-H  22-96    146-202   263-323   369-427
         22"-96"  146"-202" 263"-323" 369"-427"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  222-219'  222"-219'"
Inter-H-H  228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

namilumabum #

namilumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CSF2 (*Homo sapiens* colony stimulating factor 2 (granulocyte-macrophage), granulocyte-macrophage colony stimulating factor, GM-CSF)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231-231")-bisdisulfide dimer

namilumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CSF2 (*Homo sapiens* facteur 2 stimulant de colonies (granulocyte-macrophage), facteur stimulant des colonies de granulocytes et macrophages, GM-CSF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228-228":231-231")-bisdisulfure

namilumab

inmunoglobulina G1-kappa, anti-[CSF2 de *Homo sapiens* (*Homo sapiens* factor 2 estimulante de colonias (granulocito-macrófago), factor estimulante de colonias de granulocitos y macrófagos, GM-CSF)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV1-2*02 (89.80%) -(IGHD)-IGHJ4*01 L123>M (114)) [8.8.12] (1-119) -IGHG1*01 (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (88.40%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKAFGYPFT DYLLHWVRQA PGQGLEWVGW  50
LNPYSGDTNY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCTRTT 100
LISVYFDYWG QGTMVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS VSASVGDRVT IACRASQNIR NILNWYQQRP GKAPQLLIYA  50
ASNLQSGVPS RFSGSGSGTD FTLTINSLQP EDFATYYCQQ SYSMPRTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H   22-96    146-202    263-323    369-427
          22''-96''  146''-202''  263''-323''  369''-427''
Intra-L   23'-88'  134'-194'
          23'''-88'''  134'''-194'''
Inter-H-L  222-214'  222''-214'''
Inter-H-H  228-228''  231-231''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

299, 299''

naronapridum

naronapride

(3*R*)-1-azabicyclo[2.2.2]octan-3-yl 6-[(3*S*,4*R*)-4-(4-amino-5-chloro-2-methoxybenzamido)-3-methoxypiperidin-1-yl]hexanoate

naronapride

6-{(3*S*,4*R*)-4-(4-amino-5-chloro-2-méthoxybenzamido)-3-méthoxypipéridin-1-yl}hexanoate de (3*R*)-1-azabicyclo[2.2.2]oct-3-yl

naronaprida

6-[(3*S*,4*R*)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il]hexanoato de (3*R*)-1-azabiciclo[2.2.2]octan-3-ilo

$C_{27}H_{41}ClN_4O_5$



onartuzumabum #

onartuzumab

immunoglobulin G1-kappa monovalent Fab-Fc, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor receptor, HGFR, scatter factor receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-Met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfide with kappa light chain (1'-220') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')], (228-6":231-9")-bisdisulfide with truncated gamma1 chain consisting of partial hinge-CH2-CH3 (1"-227") [*Homo sapiens* IGHG1*01 hinge 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

onartuzumab

immunoglobuline G1-kappa monovalent Fab-Fc, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfure avec la chaîne légère kappa (1'-220') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')], (228-6":231-9")-bisdisulfure avec la chaîne gamma1 tronquée comprenant charnière partielle-CH2-CH3 (1"-227") [*Homo sapiens* IGHG1*01 charnière 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

onartuzumab

inmunoglobulina G1-kappa monovalente Fab-Fc, anti-[*Homo sapiens* MET (protooncogén met, receptor del factor de crecimiento hepatocitario, HGFR, receptor del factor de dispersión, receptor de l'HGF/SF, receptor de tirosina proteín-kinasa c-Met, carcinoma papilar de cèlulas renales 2, RCCP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV3-74*01 (77.30%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 CH3 D12>E (358), L14>M (360), T22>S (368), L24>A (370), Y86>V (409) (120-449)], (222-220')-disulfuro con la cadena ligera kappa (1'-220') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [12.3.9] (1'-113') -*Homo sapiens* IGKC*01 (114'-220')], (228-6":231-9")-bisdisulfuro con la cadena gamma1 truncada que comprende parte de la bisagra-CH2-CH3 (1"-227") [*Homo sapiens* IGHG1*01 bisagra 6-15(1"-10")-CH2(11"-120")-CH3(121"-227") CH3 D12>E (136"), L14>M (138"), T22>W (146")]

Heavy chain / Chaîne lourde / Cadena pesada (H)

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT SYWLHWVRQA PGKGLEWVGM  50
IDPSNSDTRF NPNFKDRFTI SADTSKNTAY LQMNSLRAED TAVYYCATYR 100
SYVTPLDYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLSCA VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLVS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera (L)

```
DIQMTQSPSS LSASVGDRVT ITCKSSQSLL YTSSQKNYLA WYQQKPGKAP  50
KLLIYWASTR ESGVPSRFSG SGSGTDFTLT ISSLQPEDFA TYYCQQYYAY 100
PWTFGQGTKV EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                  220
```

Hinge-CH2-CH3 / Charnière-CH2-CH3/ Bisagra-CH2-CH3 (H")

```
DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED  50
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 100
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLWCLVK 150
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 200
NVFSCSVMHE ALHNHYTQKS LSLSPGK                          227
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 146-202 263-323 369-427
Intra-H" 41"-101" 147"-205"
Intra-L 23'-94' 140'-200'
Inter-H-L 222-220'
Inter-H-H" 228-6" 231-9"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 77" unglycosylated as expressed in *Escherichia coli*

orteronelum

orteronel — 6-[(7*S*)-7-hydroxy-6,7-dihydro-5*H*-pyrrolo[1,2-*c*]imidazol-7-yl]-*N*-methylnaphthalene-2-carboxamide

ortéronel — 6-[(7*S*)-7-hydroxy-6,7-dihydro-5*H*-pyrrolo[1,2-*c*]imidazol-7-yl]-*N*-méthylnaphtalène-2-carboxamide

orteronel — 6-[(7*S*)-7-hidroxi-6,7-dihidro-5*H*-pirrolo[1,2-*c*]imidazol-7-il]-*N*-metilnaftaleno-2-carboxamida

$C_{18}H_{17}N_3O_2$



pacritinibum

pacritinib — ((2*E*,16*E*)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(25),2,4,6,8,10,12(26),16,21,23-decaene

pacritinib — (16*E*)-11-[2-(pyrrolidin-1-yl)éthoxy]-14,19-dioxa-5,7,27-triazatétracyclo[19.3.1.1^{2,6}.1^{8,12}]heptacosa-1(24),2,4,6,8,10,12(26),16,21(25),22-décaène

pacritinib — ((2*E*,16*E*)-11-[2-(pirrolidin-1-il)etoxi]-14,19-dioxa-5,7,27-triazatetraciclo[19.3.1. 1^{2,6}.1^{8,12}]heptacosa 1(25),2,4,6,8,10,12(26),16,21,23-decaeno

$C_{28}H_{32}N_4O_3$



plecanatidum

plecanatide	[3-glutamic acid(D>E)]human uroguanylin (UGN)
plécanatide	[3-acide glutamique(D>E)]uroguanyline humaine (UGN)
plecanatida	[3-ácido glutámico(D>E)]uroguanilina humana (UGN)

$C_{65}H_{104}N_{18}O_{26}S_4$

NDECELCVNV ACTGCL 16

Disulfide bridges location / Position des ponts disulfure/ Posiciones de los puentes disulfuros
4-12 7-15

pomaglumetadum methionilum

pomaglumetad methionil	(1*R*,4*S*,5*S*,6*S*)-4-(L-methionylamino)-2,2-dioxo-2λ^6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid
pomaglumétad méthionil	acide (1*R*,4*S*,5*S*,6*S*)-4-(L-méthionylamino)-2,2-dioxo-2λ^6-thiabicyclo[3.1.0]hexane-4,6-dicarboxylique
pomaglumetad metionilo	ácido (1*R*,4*S*,5*S*,6*S*)-4-(L-metionilamino)-2,2-dioxo-2λ^6-tiabiciclo[3.1.0]hexano-4,6-dicarboxílico

$C_{12}H_{18}N_2O_7S_2$



ponatinibum

ponatinib	3-[2-(imidazo[1,2-*b*]pyridazin-3-yl)ethynyl]-4-methyl-*N*-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide
ponatinib	3-[2-(imidazo[1,2-*b*]pyridazin-3-yl)éthynyl]-4-méthyl-*N*-{4-[(4-méthylpipérazin-1-yl)méthyl]-3-(trifluorométhyl)phényl}benzamide
ponatinib	3-[2-(imidazo[1,2-*b*]piridazin-3-il)etinil]-4-metil-*N*-{4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil}benzamida

$C_{29}H_{27}F_3N_6O$



ponezumabum #

ponezumab — immunoglobulin G2-kappa, anti-[*Homo sapiens* amyloid beta (A beta) peptide Aβ40], humanized monoclonal antibody; gamma2 heavy chain (1-442) [humanized VH (*Homo sapiens* IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (218-218":219-219":222-222":225-225")-tetrakisdisulfide dimer

ponezumab — immunoglobuline G2-kappa, anti-[*Homo sapiens* peptide amyloïde bêta (A bêta) Aβ40], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-442) [VH humanisé (*Homo sapiens* IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure

ponezumab — inmunoglobulina G2-kappa, anti-[péptido amiloide beta de *Homo sapiens* (A beta) Aβ40], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-442) [VH humanizada (*Homo sapiens* IGHV1-46*02 (84.50%) -(IGHD)-IGHJ6*01) [8.8.9] (1-116) -*Homo sapiens* IGHG2*01 CH2 A115>S (325), P116>S (326) (117-442)], (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-30*01 (89.00%) -IGKJ5*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímer (218-218":219-219":222-222":225-225")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYYTE AYYIHWVRQA PGQGLEWMGR  50
IDPATGNTKY APRLQDRVTM TRDTSTSTVY MELSSLRSED TAVYYCASLY 100
SLPVYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300
LTVVHQDWLN GKEYKCKVSN KGLPSSIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
DVVMTQSPLS LPVTLGQPAS ISCKSSQSLL YSDAKTYLNW FQQRPGQSPR  50
RLIYQISRLD PGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCLQGTHYP 100
VLFGQGTRLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 143-199 256-316 362-420
22"-96" 143"-199" 256"-316" 362"-420"
Intra-L 23'-93' 139'-199'
23'"-93'" 139'"-199'"
Inter-H-L 130-219' 130"-219'"
Inter-H-H 218-218" 219-219" 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
292, 292"

pracinostatum

pracinostat (2*E*)-3-{2-butyl-1-[2-(dimethylamino)ethyl]-1*H*-benzimidazol-5-yl}-*N*-hydroxyprop-2-enamide

pracinostat (2*E*)-3-{2-butyl-1-[2-(diéthylamino)éthyl]-1*H*-benzimidazol-5-yl]-*N*-hydroxyprop-2-énamide

pracinostat (2*E*)-3-{2-butil-1-[2-(dimetilamino)etil]-1*H*-bencimidazol-5-il}-*N*-hidroxyprop-2-enamida

$C_{20}H_{30}N_4O_2$



quizartinibum

quizartinib 1-(5-*tert*-butyl-1,2-oxazol-3-yl)-3-(4-{7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-*b*][1,3]benzothiazol-2-yl}phenyl)urea

quizartinib *N*-[5-*tert*-butyl-1,2-oxazol-3-yl]-*N*'-(4-{7-[2-(morpholin-4-yl)éthoxy]imidazo[2,1-*b*][1,3]benzothiazol-2-yl}phényl)urée

quizartinib 1-(5-*terc*-butil-1,2-oxazol-3-il)-3-(4-{7-[2-(morfolin-4-il)etoxi]imidazo[2,1-*b*][1,3]benzotiazol-2-il}fenil)urea

$C_{29}H_{32}N_6O_4S$



radotinibum

radotinib 4-methyl-*N*-[3-(4-methyl-1*H*-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

radotinib 4-méthyl-*N*-[3-(4-méthyl-1*H*-imidazol-1-yl)-5-(trifluorométhyl)phényl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide

radotinib 4-metil-*N*-[3-(4-metil-1*H*-imidazol-1-il)-5-(trifluorometil)fenil]-3-{[4-(pirazin-2-il)pirimidin-2-il]amino}benzamida

$C_{27}H_{21}F_3N_8O$



radretumabum #

radretumab — immunoglobulin scFv-CH dimer, anti-[*Homo sapiens* fibronectin extra domain B (ED-B)], *Homo sapiens* monoclonal antibody fragment dimer of single chain (scFv) fused with the IGHE CH4; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-5-mer linker (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-8-mer linker (350-357)]; (357:357') disulfide dimer

radrétumab — immunoglobuline scFv-CH dimère, anti-[*Homo sapiens* extra domaine B (ED-B) de la fibronectine], *Homo sapiens* anticorps monoclonal fragment dimère de scFv fusionné au CH4 de l'IGHE; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.14] (1-116)-12-mer linker (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-5-mer linker (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-8-mer linker (350-357)]; dimère (357:357')

radretumab — inmunoglobulina scFv-CH dímero, anti-[*Homo sapiens* extra dominio B (ED-B) de la fibronectina], fragmento de anticuerpo monoclonal de *Homo sapiens* dímero de scFv fusionado con el CH4 del IGHE; scFv-CH (1-357) [*Homo sapiens* VH (IGHV3-23*01 (94.90%) -(IGHD)-IGHJ4*01) [8.8.14] (1-116)-dodecámero de conexión (117-128)- *Homo sapiens* V-KAPPA (IGKV3-20*01 (94.80%) -IGKJ1*01) [7.3.9] (129-236)-pentámero de conexión (237-241)- *Homo sapiens* IGHE*01 CH4 (242-349)-octámero de conexión (350-357)]; dímero (357:357') disulfuro

scFv-CH chain / Chaîne scFv-CH / Cadena scFv-CH

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SFSMSWVRQA PGKGLEWVSS  50
ISGSSGTTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKPF 100
PYFDYWGQGT LVTVSSGDGS SGGSGGASEI VLTQSPGTLS LSPGERATLS 150
CRASQSVSSS FLAWYQQKPG QAPRLLIYYA SSRATGIPDR FSGSGSGTDF 200
TLTISRLEPE DFAVYYCQQT GRIPPTFGQG TKVEIKSGGS GGPRAAPEVY 250
AFATPEWPGS RDKRTLACLI QNFMPEDISV QWLHNEVQLP DARHSTTQPR 300
KTKGSGFFVF SRLEVTRAEW EQKDEFICRA VHEAASPSQT VQRAVSVNPE 350
SSRRGGC                                               357
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-chain	22-96	151-217	268-328
	22'-96'	151'-217'	268'-328'
Inter-chain	357-357'		

selurampanelum

selurampanel — *N*-[6-(1-methyl-1*H*-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]methanesulfonamide

sélurampanel — *N*-[6-(1-méthyl-1*H*-pyrazol-5-yl)-7-(propan-2-yl)-2,4-dioxo-1,4-dihydroquinazolin-3(2*H*)-yl]méthanesulfonamide

selurampanel — *N*-[6-(1-metil-1*H*-pirazol-5-il)-7-(propan-2-il)-2,4-dioxo-1,4-dihidroquinazolin-3(2*H*)-il]metanosulfonamida

$C_{16}H_{19}N_5O_4S$



setipiprantum

setipiprant — [8-fluoro-2-(naphthalene-1-carbonyl)-1,2,3,4-tetrahydro-5*H*-pyrido[4,3-*b*]indol-5-yl]acetic acid

sétipiprant — acide 2-[8-fluoro-2-(naphtalén-1-ylcarbonyl)-1,2,3,4-tétrahydro-5*H*-pyrido[4,3-*b*]indol-5-yl]acétique

setipiprant — ácido {8-fluoro-2-(naftalen-1-carbonil)-1,2,3,4-tetrahidro-5*H*-pirido[4,3-*b*]indol-5-il}acético

$C_{24}H_{19}FN_2O_3$



silmitasertibum

silmitasertib — 5-[(3-chlorophenyl)amino]benzo[*c*][2,6]naphthyridine-8-carboxylic acid

silmitasertib — acide 5-[(3-chlorophényl)amino]benzo[*c*][2,6]naphtyridine-8-carboxylique

silmitasertib — ácido 5-[(3-clorofenil)amino]benzo[*c*][2,6]naftiridina-8-carboxílico

$C_{19}H_{12}ClN_3O_2$



simoctocogum alfa #

simoctocog alfa — B-domain deleted human coagulation factor VIII; [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-755-arginine-756-glycine]human coagulation factor VIIIa heavy chain-(1-756)-peptide (containing F5/8 type A 1 and A 2 domains) fusion protein with human coagulation factor VIIIa light chain, glycosylated

simoctocog alfa — facteur VIII de coagulation humain dont le domaine B a été supprimé; [749-glutamine,750-alanine-751-tyrosine-753-tyrosine-754-arginine-755-arginine-756-glycine]chaîne lourde du facteur VIIIa de coagulation humain-(1-756)-peptide (contenant les domaines F5/8 type A 1 and A 2) protéine de fusion avec la chaîne légère du facteur VIIIa de coagulation humain glycosylé

simoctocog alfa — factor VIII de coagulación humano cuyo dominio B se ha suprimido; [749-glutamina,750-alanina-751-tirosina-753-tirosina-754-arginina-755-arginina-756-glicina]cadena pesada del factor VIIIa de coagulación humano-(1-756)-péptido (contiene los dominios F5/8 tipo A 1 y A 2) proteína de fusión con la cadena ligera del factor VIIIa de coagulación humano glicosilado

$C_{7459}H_{11338}N_{1992}O_{2188}S_{68}$ (peptide)

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL 50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHQA 750
YRYRRGEITR TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ 800
KKTRHYFIAA VERLWDYGMS SSPHVLRNRA QSGSVPQFKK VVFQEFTDGS 850
FTQPLYRGEL NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLISY 900
EEDQRQGAEP RKNFVKPNET KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD 950
LEKDVHSGLI GPLLVCHTNT LNPAHGRQVT VQEFALFFTI FDETKSWYFT 1000
ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL VMAQDQRIRW 1050
YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK MALYNLYPGV FETVEMLPSK 1100
AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ 1150
YGQWAPKLAR LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK 1200
FSSLYISQFI IMYSLDGKKW QTYRGNSTGT LMVFFGNVDS SGIKHNIFNP 1250
PIIARYIRLH PTHYSIRSTL RMELMGCDLN SCSMPLGMES KAISDAQITA 1300
SSYFTNMFAT WSPSKARLHL QGRSNAWRPQ VNNPKEWLQV DFQKTMKVTG 1350
VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1400
VVNSLDPPLL TRYLRIHPQS WVHQIALRME VLGCEAQDLY            1440
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 940-966 1007-1011 1129-1277 1282-1434

Sulfated residues (Y) / Résidus sulfatés (Y) / Reioduos sulfatados (Y)
Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-772 Tyr-788

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-918 Asn-1226

talimogenum laherparepvecum #

talimogene laherparepvec	recombinant replicating *Herpes simplex* type -1 virus vector, with ICP47 and both copies of ICP34.5 genes deleted, expressing human granulocyte macrophage colony stimulating factor (hGM-CSF) in the ICP34.5 loci
talimogène laherparépvec	vecteur viral *Herpes simplex* type 1 répliquant avec délétion du gène ICP47 et des deux copies du gène ICP34.5, exprimant le facteur humain de développement des polynucléaires et des macrophages (hGM-CSF) dans les loci ICP34.5
talimogén laherparepvec	vector virus del *Herpes simplex* tipo-1 replicante recombinante con delección del gen ICP47 y las dos copias del gen ICP34.5, que expresa el factor humano estimulante de colonias de granulocitos y macrógafos (hGM-CSF) in los loci ICP34.5

tedizolidum

tedizolid	(5*R*)-3-{3-fluoro-4-[6-(2-methyl-2*H*-tetrazol-5-yl)pyridin-3-yl]phenyl}-5-(hydroxymethyl)-1,3-oxazolidin-2-one
tédizolid	(5*R*)-3-{3-fluoro-4-[6-(2-méthyl-2*H*-tétrazol-5-yl)pyridin-3-yl]phényl}-5-(hydroxyméthyl)-1,3-oxazolidin-2-one
tedizolid	(5*R*)-3-{3-fluoro-4-[6-(2-metil-2*H*-tetrazol-5-il)piridin-3-il]fenil}-5-(hidroximetil)-1,3-oxazolidina-2-ona

$C_{17}H_{15}FN_6O_3$



telotristatum

telotristat	4-(2-amino-6-{(1*R* -1-[4-chloro-2-(3-methyl-1*H*-pyrazol-1-yl) phenyl])-2,2,2-trifluoroethoxy}pyrimidin-4-yl)-L-phenylalanine
télotristat	4-(2-amino-6-{(1*R*)-1-[4-chloro-2-(3-méthyl-1*H*-pyrazol-1-yl)phényl]-2,2,2-trifluoroéthoxy}pyrimidin-4-yl)-L-phénylalanine
telotristat	4-(2-amino-6-{(1*R* -1-[4-cloro-2-(3-metil-1*H*-pirazol-1-il)fenil])-2,2,2-trifluoroetoxi}pirimidin-4-il)-L-fenilalanina

$C_{25}H_{22}ClF_3N_6O_3$



tregalizumabum #

tregalizumab	immunoglobulin G1-kappa, anti-[*Homo sapiens* CD4 (T cell surface antigen T4/Leu-3, p55)], humanized monoclonal antibody; gamma1 heavy chain (1-454) [humanized VH (*Homo sapiens* IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens* IGHG1*01 (125-454)], (227-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (233-233":236-236")-bisdisulfide dimer
trégalizumab	immunoglobuline G1-kappa, anti-[*Homo sapiens* CD4 (antigène de surface T4/Leu-3 de cellule T, p55)], anticorps monoclonal humanisé; chaîne lourde gamma1(1-454) [VH humanisé (*Homo sapiens* IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens* IGHG1*01 (125-454)], (227-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (233-233":236-236")-bisdisulfure
tregalizumab	inmunoglobulina G1-kappa, anti-[CD4 de *Homo sapiens* (antígeno de superficie T4/Leu-3 de célula T, p55)], anticuerpo monoclonal humanizado; cadena pesada gamma1(1-454) [VH humanizada (*Homo sapiens* IGHV3-15*06 (77.80%) -(IGHD)-IGHJ5*01) [8.10.15] (1-124) -*Homo sapiens* IGHG1*01 (125-454)], (227-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (80.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimero (233-233":236-236")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EEQLVESGGG LVKPGGSLRL SCAASGFSFS DCRMYWLRQA PGKGLEWIGV  50
ISVKSENYGA NYAESVRGRF TISRDDSKNT VYLQMNSLKT EDTAVYYCSA 100
SYYRYDVGAW FAYWGQGTLV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSCDKT HTCPPCPAPE LLGGPSVFLF 250
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV KFNWYVDGVE VHNAKTKPRE 300
EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV SNKALPAPIE KTISKAKGQP 350
REPQVYTLPP SRDELTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT 400
TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF SCSVMHEALH NHYTQKSLSL 450
SPGK                                                    454
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSYIYWY QQKPGQPPKL  50
LIYLASILES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQHSRELPW 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-98 151-207 268-328 374-432
22"-98" 151"-207" 268"-328" 374"-432"
Intra-L 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L 227-218' 227"-218'"
Inter-H-H 233-233" 236-236"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
304, 304"

turoctocogum alfa #

turoctocog alfa — human coagulation factor VIII-(1-750)-(1638-2332)-peptide, glycosylated

turoctocog alfa — facteur VIII de coagulation humain-(1-750)-(1638-2332)-peptide glycosylé

turoctocog alfa — factor VIII de coagulación humano-(1-750)-(1638-2332)-péptido glicosilado

$C_{7480}H_{11379}N_{1999}O_{2194}S_{68}$ (peptide)

```
ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTL  50
FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGSLAKEKTQ TLHKFILLFA 200
VFDEGKSWHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPGLIGCHR 250
KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL 350
TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL 400
APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA YTDETFKTRE AIQHESGILG 450
PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI TDVRPLYSRR LPKGVKHLKD 500
FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSSFVNME RDLASGLIGP 550
LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYLTEN IQRFLPNPAG 600
VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS 650
VFFSGYTFKH KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR 700
GMTALLKVSS CDKNTGDYYE DSYEDISAYL LSKNNAIEPR SFSQNSRHPS 750
QNPPVLKRHQ REITRTTLQS DQEEIDYDDT ISVEMKKEDF DIYDEDENQS 800
PRSFQKKTRH YFIAAVERLW DYGMSSSPHV LRNRAQSGSV PQFKKVVFQE 850
FTDGSFTQPL YRGELNEHLG LLGPYIRAEV EDNIMVTFRN QASRPYSFYS 900
SLISYEEDQR QGAEPRKNFV KPNETKTYFW KVQHHMAPTK DEFDCKAWAY 950
FSDVDLEKDV HSGLIGPLLV CHTNTLNPAH GRQVTVQEFA LFFTIFDETK 1000
SWYFTENMER NCRAPCNIQM EDPTFKENYR FHAINGYIMD TLPGLVMAQD 1050
QRIRWYLLSM GSNENIHSIH FSGHVFTVRK KEEYKMALYN LYPGVFETVE 1100
MLPSKAGIWR VECLIGEHLH AGMSTLFLVY SNKCQTPLGM ASGHIRDFQI 1150
TASGQYGQWA PKLARLHYSG SINAWSTKEP FSWIKVDLLA PMIIHGIKTQ 1200
GARQKFSSLY ISQFIIMYSL DGKKWQTYRG NSTGTLMVFF GNVDSSGIKH 1250
NIFNPPIIAR YIRLHPTHYS IRSTLRMELM GCDLNSCSMP LGMESKAISD 1300
AQITASSYFT NMFATWSPSK ARLHLQGRSN AWRPQVNNPK EWLQVDFQKT 1350
MKVTGVTTQG VKSLLTSMYV KEFLISSSQD GHQWTLFFQN GKVKVFQGNQ 1400
DSFTPVVNSL DPPLLTRYLR IHPQSWVHQI ALRMEVLGCE AQDLY      1445
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 248-329 528-554 630-711 945-971 1012-1016 1134-1282 1287-1439

Sulfated residues (Y) / Résidus sulfatés (Y) / Residuos sulfatados(Y)
Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-777 Tyr-793

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-41 Asn-239 Asn-923 Asn-1231

ublituximabum #

ublituximab — immunoglobulin G1-kappa, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, B lymphocyte surface antigen B1, leukocyte surface antigen Leu-16, Bp35, CD20), chimeric monoclonal antibody;
gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-12*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfide with kappa light chain (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; (227-227''':230-230'')-bisdisulfide dimer

ublituximab — immunoglobuline G1-kappa, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A avec 4 transmembrane regions, antigène de surface B1 des lymphocytes B, antigène de surface Leu-16 des leucocytes, Bp35, CD20), anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-12*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dimère (227-227''':230-230'')-bisdisulfure

ublituximab — inmunoglobulina G1-kappa, anti-[MS4A1 de *Homo sapiens* (miembro 1 de la subfamilia A con 4 regiones , transmembrana , antígeno de superficie B1 de linfocitos B, antígeno de superficie Leu-16 de leucocitos, Bp35, CD20), anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-448) [*Mus musculus* VH(IGHV1-12*01 -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [*Mus musculus* V-KAPPA (IGKV4-72*01 -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (227-227''':230-230'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QAYLQQSGAE LVRPGASVKM SCKASGYTFT SYNMHWVKQT PRQGLEWIGG  50
IYPGNGDTSY NQKFKGKATL TVGKSSSTAY MQLSSLTSED SAVYFCARYD 100
YNYAMDYWGQ GTSVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
QIVLSQSPAI LSASPGEKVT MTCRASSSVS YMHWYQQKPG SSPKPWIYAT  50
SNLASGVPAR FSGSGSGTSY SFTISRVEAE DAATYYCQQW TFNPPTFGGG 100
TRLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H     22-96       145-201       262-322       368-426
          22''-96''     145''-201''   262''-322''   368''-426''
Intra-L     23'-87'       133'-193'
            23'''-87'''   133'''-193'''
Inter-H-L   221-213'     221''-213'''
Inter-H-H   227-227''     230-230''
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298''

urelumabum #

urelumab — immunoglobulin G4-kappa, anti-[*Homo sapiens* TNFRSF9 (tumor necrosis factor receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 hinge S10>P (229) (122-448)], (135-216')-disulfide with kappa light chain (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; (227-227":230-230")-bisdisulfide dimer

urélumab — immunoglobuline G4-kappa, anti-[*Homo sapiens* TNFRSF9 (membre 9 de la superfamille des récepteurs du facteur de nécrose tumorale, 4-1BB, antigène ILA de lymphocyte T, CD137)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 charnière S10>P (229) (122-448)], (135-216')-disulfure avec la chaîne légère kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dimère (227-227":230-230")-bisdisulfure

urelumab — inmunoglobulina G4-kappa, anti-[TNFRSF9 de *Homo sapiens* (miembro 9 de la superfamilia de receptores del factor de necrosis tumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-448) [*Homo sapiens* VH (IGHV4-34*01 (92.80%) -(IGHD)-IGHJ2*01) [8.7.15] (1-121) -IGHG4*01 bisagra S10>P (229) (122-448)], (135-216')-disulfuro con la cadena ligera kappa (1'-216') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ4*01 G119>C) [6.3.11] (1'-109') -IGKC1*01 (110'-216')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQWGAG LLKPSETLSL TCAVYGGSFS GYYWSWIRQS PEKGLEWIGE  50
INHGGYVTYN PSLESRVTIS VDTSKNQFSL KLSSVTAADT AVYYCARDYG 100
PGNYDWYFDL WGRGTLVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTK 200
TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC PAPEFLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSQE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP SSIEKTISKA KGQPREPQVY 350
TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH EALHNHYTQK SLSLSLGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD  50
ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPPALTF 100
CGGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150
KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200
QGLSSPVTKS FNRGEC                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-95	148-204	262-322	368-426
	22"-95"	148"-204"	262"-322"	368"-426"
Intra-L	23'-88'	136'-196'		
	23'"-88'"	136'"-196'"		
Inter-H-L	135-216'	135"-216'"		
Inter-H-H	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
298, 298"

usistapidum

usistapide — methyl (2*S*)-2-phenyl-2-[4-(4-{4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxamido}phenyl)piperidin-1-yl]acetate

usistapide — (+)-(2*S*)-2-phényl-2-{4-[4-({[4'-(trifluorométhyl)-[1,1'-biphényl]-2-yl]carbonyl}amino)phényl]pipéridin-1-yl}acétate de méthyle

usistapida — (2*S*)-2-fenil-2-[4-(4-{4'-(trifluorometil)-[1,1'-bifenil]-2-carboxamido}fenil)piperidin-1-il]acetato de metilo

$C_{34}H_{31}F_3N_2O_3$



vesencumabum #

vesencumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* NRP1 (neuropilin 1, NRP, vascular endothelial cell growth factor 165 receptor, VEGF165 receptor, VEGF165R, CD304) extracellular domain], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232'':235-235'')-bisdisulfide dimer

vésencumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* NRP1 (neuropiline 1, NRP, récepteur de l'isoforme 165 du facteur de croissance des cellules endothéliales vasculaires, récepteur du VEGF165, VEGF165R, CD304) domaine extracellulaire], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232'':235-235'')-bisdisulfure

vesencumab — inmunoglobulina G1-kappa, anti-[NRP1 de *Homo sapiens* (neuropilina 1, NRP, receptor de la isoforma 165 del factor de crecimiento de células endoteliales vasculares, receptor de VEGF165, VEGF165R, CD304) dominio extracelular], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma1 (1-453) [VH de *Homo sapiens* (IGHV3-23*04 (90.80%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG1*01 CH3 D12>E (362), L14>M (364) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-39*01 (89.50%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232'':235-235'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSQ  50
ISPAGGYTNY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCARGE 100
LPYYRMSKVM DVWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQYFS SYLAWYQQKP GKAPKLLIYG  50
ASSRASGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YLGSPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 150-206 267-327 373-431
22''-96'' 150''-206'' 267''-327'' 373''-431''
Intra-L 23'-88' 134'-194'
23'''-88''' 134'''-194'''
Inter-H-L 226-214' 226''-214'''
Inter-H-H 232-232'' 235-235''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

303, 303''

vidupiprantum

vidupiprant — {4-[4-(*tert*-butylcarbamoyl)-2-(2-chloro-4-cyclopropylbenzenesulfonamido)phenoxy]-5-chloro-2-fluorophenyl}acetic acid

vidupiprant — acide {4-[4-(*tert*-butylcarbamoyl)-2-(2-chloro-4-cyclopropylbenzènesulfonamido)phénoxy]-5-chloro-2-fluorophényl}acétique

vidupiprant — ácido {4-[4-(*terc*-butilcarbamoil)-2-(2-cloro-4-ciclopropilbencenosulfonamido)fenoxi]-5-cloro-2-fluorofenil}acético

$C_{28}H_{27}Cl_2FN_2O_6S$



vosaroxinum

vosaroxin — 7-[(3*S*,4*S*)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

vosaroxine — acide 7-[(3*S*,4*S*)-3-méthoxy-4-(méthylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,4-dihydro-1,8-naphtyridine-3-carboxylique

vosaroxina — ácido 7-[(3*S*,4*S*)-4-(metilamino)-3-metoxipirrolidin-1-il]-4-oxo-1-(1,3-tiazol-2-il)-1,4-dihidro-1,8-naftiridina-3-carboxílico

$C_{18}H_{19}N_5O_4S$



AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES

Recommended International Non Proprietary Names (Rec. INN): List 51
Dénominations communes internationales proposées (DCI Rec.): Liste 51
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 51
(WHO Drug Information, Vol. 18, No. 1, 2004)

p. 86 **cantuzumabum mertansinum#**

cantuzumab mertansine	replace the description and the structure by the following ones
cantuzumab mertansine	remplacer la description et la structure par les suivantes
cantuzumab mertansina	sustitúyase la descripción y la estructura por las siguientes

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242)], humanized monoclonal antibody conjugated to maytansinoid DM1;
gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer; conjugated, on an average of 4 lysyl, to maytansinoid DM1 [$N^{2'}$-deacetyl-$N^{2'}$-(3-mercapto-1-oxopropyl)-maytansine] via the reductible SPP linker [*N*-succinimidyl 4-(2-pyridyldithio)pentanoate]
For the *mertansine* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

immunoglobuline G1-kappa, anti-[*Homo sapiens* glycane sialylé de MUC1, associé à des tumeurs (CA242, antigène du cancer 242)], anticorps monoclonal humanisé conjugué au maytansinoïde DM1;
chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au maytansinoïde DM1 [$N^{2'}$-déacétyl-$N^{2'}$-(3-mercapto-1-oxopropyl)-maytansine] via le linker SPP réductible [4-(2-pyridyldithio)pentanoate de *N*-succinimidyle]
Pour la partie *mertansine*, veuillez vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"**

inmunoglobulina G1-kappa, anti-[glicano sialilado de MUC1 de *Homo sapiens*, asociado a tumores (CA242, antígeno del cáncer 242)], anticuerpo monoclonal humanizado conjugado con el maitansinoide DM1;
cadena pesada gamma1 (1-449) [VH humanizada (*Homo sapiens* IGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T (114)) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109), D125>E (110), I126>L (111)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, por término medio, en 4 grupos lisil, con el maitansinoide DM1 [$N^{2'}$-desacetil-$N^{2'}$-(3-mercapto-1-oxopropil)-maitansina] mediante el espaciador SPP reducible [4-(2-piridilditio)pentanoato de *N*-succinimidilo]
Para la *mertansina*, por favor, consulten el documento "*INN for pharmaceutical substances: Names for radicals, groups and others*"*.

cantuzumab/ cantuzumab / cantuzumab

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGETVKI SCKASDYTFT YYGMNWVKQA PGQGLKWMGW  50
IDTTTGEPTY AQKFQGRIAF SLETSASTAY LQIKSLKSED TATYFCARRG 100
PYNWYFDVWG QGTTVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPLS VPVTPGEPVS ISCRSSKSLL HSNGNTYLYW FLQRPGQSPQ  50
LLIYRMSNLV SGVPDRFSGS GSGTAFTLRI SRVEAEDVGV YYCLQHLEYP 100
FTFGPGTKLE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H  22-96    146-202   263-323   369-427
         22"-96"  146"-202" 263"-323" 369"-427"
Intra-L  23'-93'   139'-199'
         23'"-93'" 139'"-199'"
Inter-H-L  222-219'  222"-219'"
Inter-H-H  228-228"  231-231"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
299, 299"

mertansine / mertansine / mertansina



cantuzumab = $Ig(NH_2)_4$

Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales proposées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)

p. 84 **samalizumabum #**

samalizumab	replace the description by the following one
samalizumab	remplacer la description par la suivante
samalizumab	sustitúyase la descripción por la siguiente

immunoglobulin G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], humanized monoclonal antibody;
gamma2/4 heavy chain (1-442) [humanized VH (*Homo sapiens* IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-hinge-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (219-219":220-220":223-223":226-226")-tetrakisdisulfide dimer

immunoglobuline G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticorps monoclonal humanisé;
chaîne lourde gamma2/4 (1-442) [VH humanisé (*Homo sapiens* IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-charnière-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (219-219":220-220":223-223":226-226")-tétrakisdisulfure

inmunoglobulina G2/4-kappa, anti-[*Homo sapiens* CD200 (OX-2)], anticuerpo monoclonal humanizado;
cadena pesada gamma2/4 (1-442) [humanizado VH (*Homo sapiens* IGHV1-69*01 (73.50%) - (IGHD)-IGHJ4*01 L123>T (112), V124>L (113)) [8.8.10] (1-117) -*Homo sapiens* IGHG2*01 CH1-bisagra-CH2 1.6-1.1 (118-232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>del (233-442)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada(*Homo sapiens* IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G (100)) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (219-219":220-220":223-223":226-226")-tetrakisdisulfuro

p. 95 **vorapaxarum**

vorapaxar	replace the chemical name by the following

ethyl [(1*R*,3a*R*,4a*R*,6*R*,8a*R*,9*S*,9a*S*)-9-{(1*E*)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethen-1-yl}-1-methyl-3-oxododecahydronaphtho[2,3-*c*]furan-6-yl]carbamate

* *"INN for pharmaceutical substances: Names for radicals, groups & others"* document available at / document disponible à / documento disponible en :
http://www.who.int/medicines/services/inn/publication/en/index.html

Electronic structure available on Mednet: http://mednet.who.int/
Structure électronique disponible sur Mednet: http://mednet.who.int/
Estructura electrónica disponible en Mednet: http://mednet.who.int/

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.